CX Institutional’s Filana Therapeutics FLNA Stock Holding History

CX Institutional’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-800	Closed	-$22K	–	1011
2022 Q2	$22K	Buy	+800	New	+$20.2K	﹤0.01%	826

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CX Institutional's FLNA Position: Q3 2022 in Review

CX Institutional sold out of Filana Therapeutics (FLNA) in Q3 2022, closing a stake of 800 shares — an estimated $22K sold.

CX Institutional first reported a position in FLNA in Q2 2022 and held it in 1 quarter. The position peaked at $22K in Q2 2022. 175 funds tracked by Wall St. Rank hold FLNA as of Q3 2022.

CX Institutional reported no remaining Filana Therapeutics position as of Q3 2022 after selling out during the quarter.
CX Institutional sold 800 Filana Therapeutics shares in Q3 2022, an estimated $22K.
CX Institutional first reported a position in Filana Therapeutics in Q2 2022 and held it in 1 quarter.
CX Institutional's Filana Therapeutics position peaked at $22K in Q2 2022.
175 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2022.

Based on CX Institutional's 13F filing for Q3 2022, filed 4 Nov 2022.